Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002348
Status:
COMPLETED
Last Update Posted:
2020-12-19
First Post:
1999-11-02
Brief Title:
A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkins Lymphoma
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkins Lymphoma Associated With Acquired Immunodeficiency Syndrome
Status:
COMPLETED
Status Verified Date:
1996-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To estimate the response rate response duration clinical benefit and toxicity of mitoguazone dihydrochloride MGBG in patients with AIDS-related refractory or relapsing non-Hodgkins lymphoma NHL
Detailed Description:
Patients receive infusions of MGBG on days 1 and 8 and every 2 weeks thereafter It is suggested that a lumbar puncture be performed to evaluate for leptomeningeal disease
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IDD-007 | None | None | None |